RT Journal Article
SR Electronic
T1 Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.28.20142182
DO 10.1101/2020.06.28.20142182
A1 Marchioni, Camila
A1 Santos-Lobato, Bruno Lopes
A1 Queiroz, Maria Eugênia Costa
A1 Crippa, José Alexandre S.
A1 Tumas, Vitor
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.06.28.20142182.abstract
AB Background Levodopa-induced dyskinesias (LID) in Parkinson’s disease (PD) are frequent complications, and the endocannabinoid system has a role on its pathophysiology.Objective To test the hypothesis that the functioning of the endocannabinoid system would be altered in PD and in LID by measuring plasma and CSF levels of α-N-arachidonoylethanolamine (AEA) and 2-arachidonoyl-glycerol (2-AG) in patients with PD with and without LID and in healthy controls.Methods Blood and CSF samples were collected from 20 healthy controls, 23 patients with PD without LID, and 24 patients with PD with LID. The levels of AEA and 2-AG were measured using a highly sensitive column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method.Results When pooled together, patients with PD had lower plasma and CSF levels of 2-AG and higher CSF levels of AEA compared to healthy controls (Mann-Whitney statistics = 303.0, p = 0.02). Patients with PD without LID had lower CSF levels of 2-AG (Kruskal-Wallis statistics = 7.76, p = 0.02) and higher CSF levels of AEA levels than healthy controls (Kruskal-Wallis statistics = 8.81, p = 0.01).Conclusions The findings suggest that the endocannabinoid system participates in the pathophysiology of PD symptoms, but its role in the pathophysiology of LID is still unclear.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; 159688/2015-9) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; 2012/17626-7).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by institutional review board of the Ribeirão Preto Medical School (Number 3.036.243), and each participant provided written informed consent to participate.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.